Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity by Rohlwink, Ursula K. et al.
ARTICLE
Tuberculous meningitis in children is characterized
by compartmentalized immune responses and
neural excitotoxicity
Ursula K. Rohlwink 1,2,9, Anthony Figaji1,9, Katalin A. Wilkinson2,3, Stuart Horswell3, Abdul K. Sesay3,8,
Armin Deffur4, Nico Enslin1, Regan Solomons5, Ronald Van Toorn5, Brian Eley 6, Michael Levin7,
Robert J. Wilkinson 2,3,4,7 & Rachel P.J. Lai3,7
Tuberculous meningitis (TBM) is the most severe form of TB with high rates of mortality and
morbidity. Here we conduct RNA-sequencing on whole blood as well as on ventricular and
lumbar cerebrospinal fluid (CSF) of pediatric patients treated for TBM. Differential transcript
expression of TBM cases are compared with healthy controls in whole blood and with non-TB
cerebral infection controls in CSF. Whole blood RNA-Seq analysis demonstrates a distinct
immune response pattern in TBM, with significant increase in both canonical and non-
canonical inflammasome activation and decrease in T-cell activation. In ventricular CSF, a
significant enrichment associated with neuronal excitotoxicity and cerebral damage is
detected in TBM. Finally, compartmental comparison in TBM indicates that the ventricular
profile represents brain injury whereas the lumbar profile represents protein translation and
cytokine signaling. Together, transcriptomic analysis shows that disease processes differ
between the periphery and the central nervous system, and within brain compartments.
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Tuberculosis remains a major contributor to the globaldisease burden1. Dissemination to the brain results intuberculous meningitis (TBM), which is the most severe
form of TB and leads to high rates of mortality and morbidity in
both adults and children2–4. An important determinant of poor
outcome is the host inflammatory response, which results in the
formation of a thick exudate at the base of the brain. The exudate
precipitates cerebral ischemia and infarction by causing vasculitis
and occlusion of the major cerebral arteries and by disrupting the
flow of cerebrospinal fluid (CSF) causing hydrocephalus and
raised intracranial pressure. Understanding the cerebral inflam-
matory response, therefore, has been a focus of research into the
pathophysiology and treatment of TBM.
Hitherto, studies investigating the immune response in TBM
have focussed largely on immune mediators like cytokines and
chemokines, but poor outcome inconsistently associates with the
concentrations of these mediators5–7. While adjunctive ther-
apeutic intervention with corticosteroids improves short-term
mortality, it does not reduce morbidity and has no significant
influence on immune mediator concentrations4,8. Furthermore,
research on serial concentrations of biomarkers of brain injury
and inflammation in pediatric TBM demonstrated that the
inflammatory mediator concentrations decreased in all patients
within 3–4 weeks after starting treatment. However, markers of
brain tissue injury continued to increase in patients who died9. In
combination, this evidence suggests that a further characteriza-
tion of the host immune response and the consequent secondary
brain injury mechanisms set in motion is critical, and could
illuminate novel avenues for host-directed TBM treatment. In this
study we investigate the transcriptome of children with TBM at
the site of disease to elucidate key immune and injury-related
pathways. Our previous research has demonstrated the significant
differences in biomarker profiles between the periphery and site
of disease, and between compartments within the central nervous
system9. Therefore, we conduct transcriptomic analysis on blood,
lumbar CSF, and ventricular CSF.
Results
Patient characteristics. The complete patient demographics and
clinical characteristics are summarized in Table 1. Twenty TBM
cases were enrolled; median age was 3 years (min–max: 0.3–12).
Definite TBM was confirmed in 8 of the 18 patients (44%) who
had CSF sent for TB culture or GeneXpert Mtb/Rif assay (Xpert,
Cepheid). In two patients CSF was not sent for TB investigations,
one of these patients was TB positive on tracheal aspirate. Pul-
monary TB was reported in 40% (n= 8), and liver TB in 5% (n= 1)
of TBM patients. No drug resistance was detected. All patients had
associated hydrocephalus (100%) and features on contrasted brain
CT in keeping with possible TBM: basal enhancement was pre-
sented in all patients, tuberculomas were identified on admission
or follow-up scans in 30% (n= 6) of patients, and infarcts were
present on 80% (n= 16). The 12-month mortality rate was 15%
(n= 3). The three sample types were not available in all patients;
Table 1 Demographic and clinical characteristics
Characteristic TBM cases (n= 20) Non-TB infection controls (n= 7) Healthy controls (n= 24)
Demographic characteristics
Age (years) 3 (0.3–12) 1.1 (0.1–12.1) 5.1 (0·3–12.9)
Sex—male 10 (50) 6 (85.7) 19 (79.2)
CSF Investigations
Ventricular CSF
Glucose (mmol/l) 2.7 (1.5–5.4) 1.7 (0.2–1.9)
Chloride (mmol/l) 114 (105–131)
Protein (g/l) 0.8 (0.4–3) 2.3 (0.7–3.6)
Lymphocytes (/cu mm) 37 (0–140) 54 (5–440)
Polymorphonuclear cells (/cu mm) 4 (0–32) 18 (1–815)
Lumbar CSF
Glucose (mmol/l) 1.2 (<0.2–3)
Chloride (mmol/l) 107 (99–121)
Protein (g/l) 2.3 (0.9–36.7)
Lymphocytes (/cu mm) 109 (15–1785)






Admission GCS 9 (5–15)
Seizures 13 (65)
Focal neurologya 12 (60)
Meningism 9 (45)
HIV infection (n= 19)b 0 (0)
Mortality 3 (15)
CSF Investigations
TB Culture, GeneXpert or AFB positive (n= 18)c 8 (44)
Probable TBMd 12 (66)
Values are reported as median (min–max range) or number (percentage), MRC Staging refers to British Medical Research Council TBM severity staging, CSF chloride was not measured as part of clinical
routine for the non-TB infection controls, healthy controls did not have CSF sampling. Normal CSF values in pediatrics: glucose 2.3–3.9 mmol/l, chloride 120–130mmol/l, protein 0.2–0.8 g/l, zero
polymorphonuclear cells, <10 lymphocytes/cu mm
aFocal neurology included aphasia, absence of pupillary response, paresis, and cranial nerve palsies
bHIV testing was only conducted in 19 patients, the 20th patient was not tested but the patient’s mother tested negative
cCSF was sent for diagnostic testing in 18 patients, one of the remaining 2 patients tested positive for TB on tracheal aspirate
dAccording to the consensus diagnostic criteria29
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whole blood RNA was available in 15 of the 20 TBM patients and
ventricular and lumbar CSF RNA were available in 12 of the 20
TBM patients.
Twenty-seven healthy blood controls were enrolled, three were
excluded due to a positive Quantiferon result (IGRA-positive).
The remaining 24 patients had a median age of 5 years
(min–max: 0.3–12.9); 79% were boys (n= 19). Reasons
for elective surgery included intracranial pressure monitoring
(17%, n= 4), dorsal rhizotomy (13%, n= 3), fatty filum terminale
(29%, n= 7), cranioplasty (4%, n= 1), surgery for hydrocephalus
(26%, n= 6), cranio-cervical junction surgery (4%, n= 1), and
craniosynotosis (4%, n= 1). These patients did not have an
evidence of CNS inflammation at the time of sample collection.
The seven other infection (OI) controls had a median age of 1.1
years (min–max: 0.1–12.1), 86% male (n= 6). Two patients had
bacterial meningitis (Streptococcus pneumonia n= 1, no growth
on culture n= 1). Four patients had bacterial meningitis
secondary to shunt infections due to methicillin-resistant
Staphylococcus aureus (n= 1), Escherichia coli (n= 1), Staphylo-
coccus epidermidis (n= 1) and Pseudomonas (n= 1). One patient
had neurocysticercosis.
Kolomogoro–Smirnov test showed no significance in age
distribution. Healthy controls and OI controls were predomi-
nantly male, but it is unlikely that sex has a significant influence
on the pathophysiology or clinical picture of the cases or controls.
Whole blood transcriptome shows distinct immune responses.
To investigate the transcriptional responses of pediatric TBM at a
systemic level, whole blood from 39 patients (24 healthy controls
and 15 TBM cases; Supplementary Data 1) was used for RNA
sequencing. We excluded OI from final data analysis, as only four
whole blood samples were available, rendering the group inade-
quately powered.
We identified 2230 genes that were differentially expressed
between TBM cases and healthy controls using a stringent
statistical filter (log2FC > 1 and padj < 0.05) (Supplementary
Data 2). Principal component analysis on these differentially
expressed genes showed distinct separation between the TBM
cases and healthy controls (Fig. 1a). To identify cell components
mediating the systemic transcriptional response, in silico
deconvolution was performed using CIBERSORT with a validated
leukocyte gene signature matrix10. Differential gene expression in
TBM cases was driven predominantly by innate cell populations
such as neutrophils, a known marker of pathogenesis in TBM, as
well as macrophages, resting dendritic cells, and plasma B-cells
(Fig. 1b). By contrast, gene expression in the healthy controls was
predominantly associated with the CD4 (naïve, resting, and
activated memory) and CD8 T-cells.
Ingenuity pathway analysis confirmed that the differentially
expressed genes showed distinct immune responses in whole
blood (Fig. 1c and Supplementary Data 3). When compared to
the healthy controls, TBM cases showed significant upregulation
in their innate immune responses. These include antigen
recognition by pattern recognition receptors, inflammasome
activation and IL-1 signaling, all of which are components of
the proinflammatory inflammasome signaling pathways (Fig. 1d).
The whole blood signature also reflects the disease site, as
neuroinflammatory signaling was found to be upregulated in
TBM. In line with the cell subset analysis, expression of genes
over-representing T-cell activation and their signaling pathways
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Fig. 1 Whole blood transcriptome in pediatric TBM cases and IGRA-negative controls. a Principal component analysis on 2230 differentially expressed
genes between TBM and healthy controls. b Deconvolution analysis revealed the in silico cellular composition of whole blood RNA. c Ingenuity canonical
pathways overrepresented by differentially expressed genes are shown. The z-score indicates whether the pathway was upregulated (red) or
downregulated (blue) in TBM. d Inflammasome signaling pathway is depicted. Molecules colored in red were significantly upregulated in TBM, compared
to the controls. e T-cell activation pathway is shown. Molecules colored in blue were significantly downregulated in TBM, relative to the healthy controls
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We further performed sub-analyses to dissect the impact of
several covariates and found that sex, TBM diagnosis (definite vs.
probable) or TBM stage all had no influence in the whole blood
transcriptomes. Age had a minor impact on the transcriptional
responses in both TBM cases and healthy controls (0.47 and
0.16% of the transcriptome, respectively). The effect of age is also
minute when considered as an interactive covariate in differential
expression analysis comparing the two patient groups, as 2166/
2230 genes remained significant and the functional pathways
identified remained unchanged.
Cerebral transcriptome reveals increased excitotoxicity. To
better understand the cellular response in the brain, we profiled
the global transcriptomes of ventricular CSF by sequencing. This
was compared to the transcriptome of the non-TB OI controls.
We did not directly compare the transcriptomic data from the
CSF to those of the blood as the different library preparation used
to accommodate for the low quantity (picogram range) of CSF
RNA would compromise the compatibility of differential gene
expression analysis. We analyzed ventricular CSF RNA-Seq data
from 12 TBM cases (five definite and seven probable) and seven
OI controls (Supplementary Data 4) and identified 312 genes that
were differentially expressed (padj < 0.05) and which segregated
the two groups by principal component analysis (Fig. 2a and
Supplementary Data 5).
To understand the biological processes involved, we performed
Gene Set Enrichment Analysis on the whole transcriptome pre-
ranked on the Wald statistic. Immunological pathways such as
those associated with cytokine signaling and toll-like receptor
signaling were negatively enriched in TBM when compared with
OI controls, with IL-1 and TNF being significantly downregulated
(Fig. 2b and Supplementary Data 6). In addition, neutrophil-
associated markers, such as S100A8, matrix metalloproteinases
(MMP9/19/25) and tissue inhibitor of MMP (TIMP1) were all
found to be significantly decreased in TBM. These inflammatory
mediators have been found to be highly upregulated in blood or
lumbar CSF of TBM11–13. In contrast, several pathways associated
with glutamate neurotransmitter release, NMDA receptor bind-
ing and uptake were positively enriched in TBM (Fig. 2b),
indicating that neuronal excitotoxicity was prominent in the
ventricular CSF during TBM infection. Intriguingly, hierarchical
clustering showed differential separation of patients with
probable TBM (Fig. 2c). Post-hoc review found that the probable
cases that cluster closely with definite TBM (definite-like) all had
classical findings of TBM on brain imaging (e.g., precontrast basal
hyperdensity, basal meningeal enhancement, typical pattern of
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Fig. 2 Transcriptome of ventricular CSF in pediatric TBM and other infection controls (OI). a Principal component analysis based on 312 differentially
expressed genes between TBM and OI control is shown. b Reactome pathways enriched in TBM, relative to the controls, are listed. The normalized
enrichment score indicates whether the pathway is positively enriched (red) or negatively enriched (blue) in TBM. c Heatmaps depicting the log2-
transformed gene expression associated with glutamate release, NMDA receptor binding, or GABA degradation in the TBM group and the OI group. Each
row represents one gene. d Heatmaps depicting the log2-transformed gene expression associated with glutamate release, NMDA receptor binding, or
GABA degradation in relation to TBM diagnosis. e Reactome pathways enriched in OI-like probable TBM cases (blue), relative to definite or definite-like
probable TBM cases (red) are listed
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11783-9
4 NATURE COMMUNICATIONS |         (2019) 10:3767 | https://doi.org/10.1038/s41467-019-11783-9 | www.nature.com/naturecommunications
four probable cases that cluster with OI controls (OI-like) were
found to have atypical imaging features (Supplementary Fig. 1).
To further explore the differential clustering among the seven
probable TBM cases, subgroup analysis was performed to
characterize gene expression between definite TBM (n= 5),
definite-like probable TBM (n= 3), and OI-like probable TBM
(n= 4). There was no transcriptional difference between definite
TBM and definite-like probable cases, but significant transcrip-
tional differences were consistently detected in 1815 genes
(padj < 0.05), when comparing OI-like probables to definite
TBM, as well as to definite-like probable cases (Fig. 2d and
Supplementary Data 7). Gene Set Enrichment Analysis found that
while definite and definite-like probable cases were enriched in
pathways associated with glutamate neurotransmitter release,
NMDA receptor binding, and GABA degradation, the OI-like
probable cases were associated with immune response pathways
such as antigen presentation, type I and type II interferon
signaling and IRF7 activation (Fig. 2e and Supplementary Data 8).
Sub-analysis on the other covariates was also performed, but
neither age, gender, mortality, nor stages of TBM had any
significant impact on the CSF transcriptome. The results
indicated that heterogeneity within all 12 TBM cases arose
predominantly from those diagnosed with probable TBM, where
there were two distinct subsets of patients.
Distinct biological processes in lumbar and ventricular CSF.
We compared the transcriptomes between lumbar and ventricular
CSF from our TBM cases (n= 12). Differential gene expression
analysis identified 389 significantly different genes (Fig. 3a and
Supplementary Data 9). In silico deconvolution on cellular
composition with total transcriptomes revealed differences in
leukocyte infiltration into the two different sites. Neutrophil
transcripts were found to have predominantly higher presence in
the lumbar CSF than in the ventricle (Fig. 3b). In contrast, other
cellular subsets such as B-cells (memory and plasma), monocytes,
and activated DCs, as well as nonneutrophil granulocytes were
found in higher abundance in the ventricles.
Similar to ventricular CSF results above, Gene Set Enrichment
Analysis revealed a strong positive enrichment in neuronal
pathways, such as those associated with neurotransmitter release
and neural tissue damage in ventricular CSF (Fig. 3c and
Supplementary Data 9). In addition, increased transcription of
genes associated with the potassium channel as well as nitric
oxide stimulation were also identified (Supplementary Data 10).
Disease network analysis on the 389 differentially expressed genes
strongly indicated neurological disease and injury in the ventricle
(p= 2.62 × 10−13, Fisher’s exact test), where 45/46 associated
genes were upregulated (Fig. 3d). These 45 genes are mainly
associated with glutamate excitotoxicity, a known mediator of
many neurological diseases. In contrast, the lumbar CSF
presented a substantially different transcriptomic landscape.
Enhanced RNA transcription and protein translation, as well as
cytokine signaling, were all overrepresented in lumbar CSF
(Fig. 3c).
Given that probable TBM cases demonstrated two subgroups
(definite-like and OI-like) in ventricular CSF, subgroup analysis
was performed on the lumbar CSF transcriptomes. Surprisingly,
no transcriptional difference was detected when comparing
OI-like probable cases to definite TBM or to definite-like
probable cases (Fig. 3e). Other co-variate analyses failed to find
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Fig. 3 Transcriptome of ventricular CSF in comparison to lumbar CSF. a A heatmap depicting 389 differentially expressed genes between ventricular and
lumbar CSF in pediatric TBM patients. b Deconvolution analysis revealed the in silico leukocyte composition of ventricular and lumbar CSF, respectively. c
Reactome pathways enriched in ventricular CSF, relative to the lumbar are shown. The normalized enrichment score indicates whether the pathway is
positively enriched (red) or negatively enriched (blue) in the ventricle of TBM patients. d Ingenuity disease network analysis clustered 46 of the
differentially expressed genes into a network associated with neurological disease and injury. Molecules colored in red were significantly upregulated in
ventricular CSF compared to lumbar CSF, while blue indicates significant downregulation. e A heatmap depicting the log2-transformed gene expression
associated with glutamate release, NMDA receptor binding, or GABA degradation in relation to TBM diagnosis in lumbar CSF
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Discussion
In this study we characterized the transcriptome of the whole
blood, as well as two different sites of CSF (brain and spinal), to
investigate disease processes occurring due to TBM. The main
findings indicated a compartmentalized immune response in the
peripheral blood and a gene signature overrepresented by neural
injury in the CSF, particularly in the ventricular CSF. This is the
first comprehensive analysis to date of both blood and CSF
transcriptomes in TBM.
The pathogenesis of TBM is poorly understood due to the lack
of an appropriate experimental model and the challenge of
sampling the site of disease. Cohort studies in adults14 and in
children15 have identified transcriptional signatures that could
differentiate pulmonary TB from other infections, but whether
these signatures can be applied for TBM remains to be investi-
gated. A recent study used microarray to profile the whole blood
transcriptomes of children with TBM at multiple time points and
delineated reduced T-cell proliferation and immune responses
over the course of disease progression16. While our study did not
examine transcriptional changes over time, we identified a similar
transcriptional reduction in peripheral T-cell responses when
TBM cases were compared to IGRA-negative healthy controls.
Intriguingly, a strongly upregulated innate immune response
driven by inflammasome activation in whole blood was also
identified. Our previous study on TBM-associated immune
reconstitution inflammatory syndrome in adults also identified
increased inflammasome signaling in the whole blood tran-
scriptome and at protein level in the CSF17, further suggesting
that inflammasome activation is a feature of TBM at the systemic
level. In vitro and murine models of TB demonstrate that
IFNγ and IFNγ-induced nitric oxide production are required to
inhibit the NLRP3 inflammasome and the subsequent production
of IL-1β to prevent neutrophil recruitment and tissue damage18.
Thus, the lack of an effective T-cell response in pediatric TBM
might be a contributing factor to the upregulated inflammasome
activation.
Given the lack of access to brain tissues, we therefore utilized
ventricular CSF as a proxy to study the cellular and immunolo-
gical events in the brain. We have previously reported that ven-
tricular CSF has significantly higher concentrations of cerebral
injury markers relative to lumbar CSF9. This is in keeping with
the cerebral site of production of these markers and the known
rostro-caudal decrement in brain-derived proteins as CSF flows
from the brain to the spinal canal19,20. Consistent with these data
the transcriptomic signature in ventricular CSF revealed sig-
nificant enrichment associated with neural excitotoxicity pre-
dominantly driven by glutamate release, NMDA receptor binding
and uptake, features also associated with other forms of brain
injury. Glutamate is a key excitatory neurotransmitter with
important roles in learning and memory21. TBM-induced
infarction and ischemia could potentially stimulate glutamate
release22, leading to the excessive binding of glutamate to NMDA
receptors on neurons. This precipitates an influx of Ca2+ and
other positive ions into the neuron, resulting in the production of
calpains, caspases, endonucleases, and phospholipases, and begins
a cascade of injury mechanisms23. These include mitochondrial
damage, breakdown of the cell membrane and cytoskeleton,
production of nitric oxide and free radicals, acidosis, and DNA
fragmentation, subsequently leading to apoptotic or necrotic cell
death24,25. Our transcriptomic data also showed upregulation of
genes associated with nitric oxide, cytochrome c, brain injury
proteins like myelin basic protein, and proteins associated with
neurodegenerative disease, including tau, amyloid-beta and apo-
lipoprotein E. Excessive glutamate and neuro-excitotoxicity are
thought to contribute to brain injury and cell death in both acute
brain injury conditions, such as traumatic brain injury (TBI) and
epilepsy, and chronic brain disorders such as Alzheimer’s and
Huntington’s disease26–28. Excitotoxicity may increase the risk of
clinical and subclinical seizures in TBM, and of cortical spreading
depression, a secondary injury mechanism known to occur in
stroke. These electrophysiological events increase metabolic
demand on the already ischemic brain. Our data reflect the
clinical picture of brain infarction in our TBM cases demon-
strated on imaging, and begin to illuminate various brain injury
mechanisms set up by the inflammatory response and the con-
sequent ischemia.
Validation and targeted investigation of these excitotoxic
mechanisms could identify novel therapeutic agents to ameliorate
the ongoing brain injury. Recent data in mild TBI suggest chronic
low-level neuroinflammatory processes may be initiated by minor
insults like concussion and lead eventually to neurodegenerative
disease if they occur repeatedly24. The considerable damage and
inflammation precipitated by TBM may initiate similar long-term
processes and poor outcomes. The differences between cases and
controls indicate that it is unlikely that these findings simply
reflect hydrocephalus or the method of ventricular puncture.
Intriguingly, on further examination of the excitotoxicity sig-
nature probable TBM cases differentiated into two subgroups:
those with transcriptomic profiles more similar to the definite
cases and those who were more closely related to OI controls.
Posthoc analysis of their CT scans demonstrated differences
between these two groups as well (Supplementary Fig. 1). Given
that CSF culture positivity is low in most series, the diagnosis of
TBM often relies on a suggestive history, clinical symptoms, CSF
labs, and brain imaging findings. In the absence of a definitive
“rule-out” test for TBM, it is not possible to determine whether
probable cases are true TBM positive, or false positive. These data
suggest that the transcriptional signature from ventricular CSF
may be a possible way to identify different subgroups within the
broad TBM diagnostic spectrum, thus avoiding unnecessary
treatment and inappropriate inclusion in clinical trials. However,
we caution that this hypothesis was generated from a small
number of patients and posthoc analysis. Further prospective
research would be needed to replicate and further explore this
finding.
Although lumbar CSF is commonly used to study disease and
treatment processes in TBM, our data on inflammatory and brain
injury biomarkers in TBM demonstrate that ventricular CSF may
be more representative of brain injury processes while lumbar
CSF reflects inflammation. These compartmental differences are
exemplified both at a clinical level in the chemistry data (Table 1)
and also at transcriptional level. In silico deconvolution analysis
in this study inferred a marked difference in cell composition
between the lumbar and the ventricular space, where neutrophils
were the dominant leukocytes in the lumbar CSF but showed low
transcriptomic abundance in the ventricle. The predominance of
monocytes in the ventricular CSF may reflect the local microglial
response in the brain. Furthermore, the ventricular CSF neural
injury signature was not present in the lumbar CSF, consistent
with our biomarker work, which showed a greater concentration
of cytokines and chemokines in the lumbar space and brain injury
biomarkers in the ventricle9. Lumbar CSF did not show a tran-
scriptional difference between definite and probable TBM cases,
or within the probable group. This is likely because the tran-
scriptional heterogeneity in probable TBM predominantly came
from genes associated with excitotoxicity, which have low
expression in lumbar CSF compared to ventricular CSF. Future
larger studies with an increased sequencing read depth could
improve the resolution of the transcriptional profiles in the
lumbar CSF and may detect further heterogeneity within the
TBM cases. These data highlight the importance of considering
compartments in the central nervous system as distinct and
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evaluating ventricular CSF, when sampling is feasible, can offer
novel insights into TBM pathogenesis.
We acknowledged that the small volume of CSF available in
these young patients after clinical imperatives had been met
limited the volume of CSF available for RNA extraction, espe-
cially since CSF cell counts are relatively low for RNA work.
However, it is the first study to examine whole transcriptomics in
the CSF of TBM patients, and offers insight into disease
mechanisms to encourage further studies. The patients in this
study all had hydrocephalus and the results in the absence of
hydrocephalus may be dissimilar. However, it was by virtue of the
need for CSF diversion that we were able to collect excess CSF for
analysis, and the majority of pediatric TBM cases present with
hydrocephalus. The non-TB infection control group presented
with an acute rather than subacute inflammatory process (as
exemplified in Fig. 2d), and shunt-related ventriculitis is not
commonly associated with brain infarction. This may have con-
tributed to the abundance of injury transcripts in the cases rela-
tive to controls; however, this was the most suitable diseased
control group from whom we had access to sufficient CSF.
In conclusion, pediatric TBM appears to be characterized by an
inflammasome-driven peripheral immune response, and brain
injury appears to represent an important component of disease
pathophysiology. There are important compartmental differences in
TBM patients that are relevant to research studies. The disease
pathways elucidated in this study offer valuable insight into
potential targets for novel interventions that require further study.
Methods
Ethics. This study was approved by the scientific and human ethics review com-
mittees of the Faculty of Health Sciences of the University of Cape Town (HREC
200/2014). Parents/guardians provided informed consent for all study patients.
Children older than 7 years provided assent as per South African national
guidelines.
Study cohorts. Patients treated for probable or definite TBM admitted to the Red
Cross War Memorial Children’s Hospital, Cape Town, between July 2014 and
February 2016 were recruited. TBM diagnosis was based on the consensus research
definition, which combines clinical, radiological, and laboratory characteristics29.
One patient was recruited from Tygerberg Hospital, Cape Town. All patients
received standard antimycobacterial and adjunctive corticosteroid treatment30.
Associated hydrocephalus was treated according to our institutional protocol31.
Clinical data included admission signs and symptoms, demographics, death within
12 months, and radiological outcome, collected from admission and follow-up
computed tomographic and/or magnetic resonance imaging brain scans. TBM
disease severity was categorized using the refined British Medical Research Council
criteria: Stage I: Glasgow Coma Score (GCS) 15 with no neurological deficit, Stage
IIa: GCS 15 with neurological deficit/GCS13-14 with/without neurological deficit,
Stage IIb: GCS 10–12 with/without neurological deficit, Stage III: GCS < 10 with/
without neurological deficits32,33. Two control groups were enrolled; first, a group
of patients undergoing elective neurosurgery for noninfectious conditions (healthy
controls) from whom we collected blood; second, patients with meningitis or
ventriculitis of non-TB origin (non-TB infection controls) from whom we collected
blood and ventricular CSF. Since these patients required neurosurgical intervention
with ventricular rather than lumbar puncture, lumbar CSF was not sampled. In
those patients in whom lumbar punctures were performed, the small volumes of
CSF obtained were prioritized for clinical imperatives.
Sample collection. Blood samples from cases and controls were collected during
clinically indicated venepuncture on admission or at surgery. Lumbar CSF was col-
lected from cases during routine lumbar punctures for diagnostic or treatment pur-
poses. Ventricular CSF was collected from cases and non-TB infection controls during
clinically indicated neurosurgical interventions including insertion of an external
ventricular drain or ventriculoperitoneal shunt. All samples were collected before or
within 48 h of the first dose of anti-tuberculous treatment. Where possible samples
across compartments were time-linked. Healthy controls also had blood collected for
QuantiFERON TB Gold (QIAGEN) analysis to ascertain TB exposure.
RNA extraction and sequencing library preparation. Whole blood (1–2.7 ml)
was collected in PAXgene Blood RNA Tubes (QIAGEN/BD Biosciences), and total
RNA was extracted using the PAXgene Blood RNA Kit (QIAGEN, Venlo, Neth-
erlands). QuantiFERON testing was conducted using the QuantiFERON ELISA kit
(QIAGEN). CSF was prioritised for clinical investigations and the remaining fluid
was stored in RNA preservation buffer at −80 °C until RNA extraction was per-
formed. RNA was extracted using the Direct-zol™ RNA MiniPrep kit (Zymo
Research, Irvine, CA). The quantity and quality of the extracted RNA were mea-
sured by the Qubit fluorometer and the Caliper LabChip system, respectively. RNA
libraries for whole blood RNA were constructed using the Ovation Human Blood
RNA-Seq Library Systems (NuGEN Technologies, Red Wood City, CA) where
ribosomal and globin RNA were removed according to the manufacturer’s pro-
tocol. RNA libraries for CSF RNA were constructed using the Ovation SoLo RNA-
Seq system (NuGEN Technologies) due to the low quantity available. The final
libraries were assessed using TapeStation 2200 System (Agilent, Santa Clara, CA).
All libraries were sequenced on Illumina Hi-Seq 4000 instrument with paired-end
100 cycle reactions.
RNA-Seq data analysis. The quality of the sequencing fastq files was analyzed
using FastQC (v0.11.5) and poor quality samples were excluded from further
differential gene expression analysis. Sequence reads were adapter- and quality-
trimmed using Trimmomatic (v0.36) before aligning to the human genome
(Ensembl GRCh38 build 88) using STAR aligner (v2.5.2a). Gene expression was
quantified using RSEM (v.1.2.29), and differential gene expression analysis was
performed using DESeq2 (v1.20.0) with default parameters for whole blood and
with gene filtering (threshold ≥1) for CSF. DESeq2 uses a generalized linear model
to estimate log2 fold change (log2FC) between comparison groups and the
Benjamini-Hochberg false discovery rate was applied for multiple testing correc-
tions, resulting in an adjusted p-value (padj) for each gene per comparison. Gene
Set Enrichment Analysis on the whole transcriptome was performed by preranking
all genes to the Wald statistic and referenced to the Reactome biological pathway
database. Functional canonical pathways and disease networks associated with the
differentially expressed genes were identified using Ingenuity IPA (QIAGEN).
Role of the funding source. The funders of this study were not involved in the
study design, data collection, data analyses, data interpretation, or report pre-
paration. The corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All RNA-Seq data has been deposited to Gene Expression Omnibus with accession
number SE111459 for whole blood data and GSE122377 for CSF data.
Code availability
All computer codes used in the study follow the vignette of each analytical package and
are publically accessible. No customized code was used.
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